Followers | 1 |
Posts | 1 |
Boards Moderated | 0 |
Alias Born | 12/15/2014 |
Monday, December 15, 2014 1:39:23 PM
I am new to this board. I have been an investor of ONCS for over a year.
Seeing that there has been a lot of confusion as to the value of Immunopulse, I would like to provide a valuation case. It goes a bit into the science and the positioning of Immunopulse within the fast-moving immunotherapy space.
http://tinyurl.com/o4zztqf
Fundamentally, ONCS closest comparison is Tvec (acquired for $1B by Amgen in 2011). Both are being evaluated as combination therapies with Merck's PD1. Both have a very similar mechanism of action. The upcoming Immunopulse+PD1 trial has been significantly de-risked by Tvec's combination Yervoy trial results (mid-2014).
Best,
Justice
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM